Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy

The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: Baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH) trial

(2011)   AMERICAN HEART JOURNAL

MR Imaging of Carotid Plaque Composition During Lipid-Lowering Therapy

(2011) Xue-Qiao Zhao et al.   JACC-Cardiovascular Imaging

The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6–HDL and LDL Treatment Strategies in Atherosclerosis)

(2010) Todd C. Villines et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

Frequency of Obtaining National Cholesterol Education Program Adult Treatment Panel III Goals for All Major Serum Lipoproteins After Initiation of Lipid Altering Therapy††Conflicts of interest: Drs. Nichols and Brown are employees of Kaiser Permanente Northwest. Drs. Ambegaonkar and Sazonov are employees of Merck & Company, Inc. Drs. Nichols and Brown have received research support from Amgen, Inc., Thousand Oaks, California; Novo Nordisk A/S, Bagsværd, Denmark; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; Takeda Pharmaceuticals North America, Inc., Deerfield, Illinois; and GlaxoSmithKline, Inc., London, United Kingdom.

(2009) Gregory A. Nichols et al.   AMERICAN JOURNAL OF CARDIOLOGY

Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis

(2009) Eric Bruckert et al.   ATHEROSCLEROSIS

Heart Disease and Stroke Statistics—2010 Update

(2009) et al.   CIRCULATION